Bei Akademie registrieren
MDRX, US01988P1084

Veradigm stock: Security portfolio earns HITRUST certification

Published on 10/30/2026 at 02:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Veradigm stock is tied to a new security milestone across its healthcare technology portfolio. The certification may support customer assurance and compliance reviews.

Security certification expands Veradigm's assurance profile

  • Veradigm said an independent assessment confirmed security controls across a broad set of healthcare technology solutions.
  • The certified portfolio spans electronic health records, practice management, payer analytics, and revenue-cycle products.
  • The certification provides customers and partners with a standardized assurance signal for security reviews.
MDRX, US01988P1084, Illustration mit AI erstellt.
MDRX, US01988P1084, Illustration mit AI erstellt.

Veradigm announced on October 21, 2026, that a broad set of its healthcare technology solutions had achieved HITRUST i1 Certification. The company described the certification as an independently assessed validation of security controls; the announcement was reported by Business Wire.

Independent validation across core products

HITRUST i1 is a threshold-based assessment built around current security practices. According to Veradigm, earning the certification required the relevant controls to be implemented, operational, and verified through an independent assessment rather than self-attestation.

The certified solutions include Veradigm EHR, Veradigm Practice Management, Practice Fusion, Veradigm ePrescribe, Payerpath, FollowMyHealth, Transaction Hub, and several eChart, payer, quality, and revenue-cycle offerings. The breadth of the portfolio gives the announcement relevance beyond a single product line.

Why the announcement matters

For healthcare technology providers, independently validated security controls can reduce uncertainty during customer and partner reviews. Veradigm said the certification offers a standardized assurance signal for clients and prospective clients handling sensitive healthcare data.

The announcement does not by itself quantify revenue, margins, customer additions, or near-term cash-flow effects. Its investor relevance is therefore mainly strategic: stronger compliance credentials may help support trust in a market where data protection is an important purchasing consideration.

Veradigm company facts

  • Company: Veradigm
  • ISIN: US01988P1084
  • Ticker: MDRX
  • Trading venue: OTC market
  • Sector focus: Healthcare data, clinical, and revenue-cycle solutions

Healthcare investors are also assessing broader cybersecurity and software-sector developments through the S&P 500 market environment.

For further company-specific coverage, see More news and analyses on Veradigm stock.

Disclaimer...
en | US01988P1084 | MDRX | boerse | 70431987 |